Skip to main content Skip to footer


In brief

An evolution of engagement


Pharma companies need to do more to better understand and meet the expectations of HCPs due to COVID-19.


When pharma companies do more, they are recognized and rewarded by HCPs with more time and attention.


HCPs most value connections that blend the best of virtual and in-person, focused on the needs of their patients.

Sixty-five percent of HCPs feel at least one pharma company has “spammed” them with digital content as the COVID-19 pandemic has evolved.


of HCPs have seen a decrease in patient numbers over the past year.


have more capacity available than before COVID-19.

Eighty-eight percent of HCPs would be twice as likely to meet with other companies/reps if their best relationship was replicated.

Continuously challenge what defines relevance

84% of HCPs believe the content they are receiving from pharma companies today is more relevant than before the COVID-19 crisis.

Don’t view the field force as a separate channel

44% of HCPs said discussions with pharma representatives are the most dominant factors shaping their treatment decisions.

Minimize the content clutter

41% of HCPs said they would be more willing to open emails and listen to messages from a company if their best interaction was replicated.

Laura Dix

Managing Director – Life Sciences, United Kingdom

Suzy Jackson

Managing Director – Life Sciences

Ramon Pressburger

Managing Director – North America Lead and Strategy Lead, Global Life Sciences

Visit our Subscription and Preference Center